Compare · ANIX vs NVO
ANIX vs NVO
Side-by-side comparison of Anixa Biosciences Inc. (ANIX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANIX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 1797.0x ANIX ($96.6M).
- ANIX has been more active in the news (8 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 2 for ANIX).
- Company
- Anixa Biosciences Inc.
- Novo Nordisk A/S
- Price
- $2.67-3.78%
- $38.82-1.05%
- Market cap
- $96.6M
- $173.66B
- 1M return
- -
- -10.14%
- 1Y return
- -
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 4
- Recent ratings
- 2
- 25
Anixa Biosciences Inc.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANIX
- Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
- Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
- Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
- President, COO, & CFO Catelani Michael bought $15,620 worth of shares (5,500 units at $2.84), increasing direct ownership by 12% to 50,000 units (SEC Form 4)
- Chief Executive Officer Kumar Amit bought $19,460 worth of shares (7,000 units at $2.78), increasing direct ownership by 1% to 672,000 units (SEC Form 4)
- Director Baskies Arnold M bought $13,800 worth of shares (5,000 units at $2.76), increasing direct ownership by 4% to 140,572 units (SEC Form 4)
- Director Titterton Lewis H Jr bought $131,907 worth of shares (49,036 units at $2.69), increasing direct ownership by 5% to 1,046,003 units (SEC Form 4)
- Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
- Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
- Chief Executive Officer Kumar Amit bought $8,250 worth of shares (3,000 units at $2.75), increasing direct ownership by 0.45% to 665,000 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank